Evaluation of the high-throughput RespiV <i>PlexP</i> <i>lus</i> multiplex assay compared to BioFire Respiratory Panel 2.1 <i>plus</i>

are slower and more labor-intensive for small batches but optimized for large batch processing on standard molecular diagnostic platforms. They offer higher throughput with lower consumable costs, making them suitable for centralized laboratories. Recent innovations in both sample-to-answer and conventional multiplexing technologies have expanded detectable targets, with comparable technical performance between formats. Ultimately, the optimal choice depends on healthcare system resources and testing demands.